Roche Holding AG: Funding the Genentech Acquisition Custom Case Solution & Analysis

Case Evidence Brief: Roche Holding AG

Financial Metrics

• Current Ownership: Roche owns 55.8 percent of Genentech outstanding shares.
• Initial Proposal: 89.00 USD per share offered on July 21, 2008, representing a total cash consideration of 43.7 billion USD.
• Revised Hostile Tender: 86.50 USD per share offered on January 30, 2009, following the collapse of Lehman Brothers and a decline in equity markets.
• Genentech Counter-Valuation: The Genentech Special Committee valued the minority stake between 112.00 and 115.00 USD per share.
• Roche Liquidity: 16.3 billion CHF in cash and marketable securities as of December 31, 2008.
• Financing Requirement: Roche needs to raise approximately 40 billion USD in debt markets, which would be the largest corporate bond offering in history.
• Market Conditions: Credit spreads for A-rated corporate debt increased from 150 basis points in early 2008 to over 500 basis points in late 2008.

Operational Facts

• Structure: Genentech operates as a semi-independent entity with its own board and headquarters in South San Francisco.
• Product Pipeline: Genentech provides the majority of Roche oncology revenue through Avastin, Herceptin, and Rituxan.
• Geography: Roche is headquartered in Basel, Switzerland; Genentech is based in the United States.
• Debt Strategy: Roche aims to issue bonds in multiple currencies including USD, EUR, and GBP to diversify funding sources.

Stakeholder Positions

• Franz Humer (Roche Chairman): Driving the full integration to capture all cash flows and streamline R&D.
• Severin Schwan (Roche CEO): Tasked with executing the acquisition during the worst financial crisis since the Great Depression.
• Charles Sanders (Genentech Special Committee Chair): Rejection of the 89.00 USD and 86.50 USD offers as substantially undervaluing the company.
• Genentech Scientists: Fearful of a loss of autonomy and the imposition of Swiss corporate bureaucracy on a biotech culture.

Information Gaps

• Precise retention cost for key Genentech scientific talent post-merger.
• Final interest rate coupons for the multi-tranche bond offering.
• Specific tax liabilities arising from the repatriation of Genentech cash to Switzerland.

Strategic Analysis

Core Strategic Question

• How can Roche successfully finance and execute the full acquisition of Genentech during a global liquidity crisis without destroying the target scientific culture or compromising the credit rating of the parent company?

Structural Analysis

The strategic tension resides in the Value Chain. Genentech represents the R&D engine, while Roche provides the global commercialization and distribution infrastructure. The existing majority-ownership structure creates friction, including duplicative administrative costs and misaligned incentives regarding pipeline investment. However, the bargaining power of the supplier—in this case, Genentech scientific talent—is high. A hostile takeover risks an exodus of the human capital that justifies the 40 billion USD price tag.

Strategic Options

Option 1: Maintain the Hostile Tender at 86.50 USD. This preserves Roche capital and capitalizes on the weak 2009 equity market. However, it almost guarantees a prolonged legal battle with the Special Committee and deepens resentment among Genentech staff. The probability of reaching the 90 percent squeeze-out threshold is low.

Option 2: Negotiate a Friendly Settlement at 93.00 to 95.00 USD. This price point sits between the initial offer and the Special Committee demands. It secures board recommendation, which is vital for a smooth transition and talent retention. It increases the debt burden by approximately 4 billion USD but reduces the execution risk of the tender offer.

Option 3: Withdraw the Offer and Re-evaluate in 12 Months. This avoids the high cost of debt in the current market. The trade-off is the continued inefficiency of the dual-structure and the risk that Genentech share price recovers, making a future acquisition significantly more expensive.

Preliminary Recommendation

Roche should move to Option 2. The strategic value of full ownership—specifically the ability to control 100 percent of the free cash flow from Avastin and Herceptin—outweighs the incremental cost of a higher offer. A negotiated settlement is the only path that protects the innovation culture. Roche must move quickly to exploit the current window in the investment-grade bond market before further macroeconomic deterioration occurs.

Implementation Roadmap

Critical Path

• Phase 1 (Days 1-15): Price discovery and negotiation. Increase offer to 95.00 USD contingent on Genentech Board approval.
• Phase 2 (Days 16-45): Massive multi-tranche bond issuance. Launch simultaneous roadshows in London, New York, and Zurich to raise 40 billion USD.
• Phase 3 (Days 46-60): Close the tender offer. Complete the short-form merger once ownership exceeds 90 percent.
• Phase 4 (90-Day Post-Close): Establish the South San Francisco site as the independent center for Genentech Research and Early Development (gRED) to signal cultural continuity.

Key Constraints

• Market Capacity: The sheer size of the debt issuance may saturate investor appetite for healthcare paper, requiring higher yields than historical averages.
• Talent Flight: The transition from an independent California biotech to a subsidiary of a Swiss conglomerate creates immediate retention risks for top-tier scientists.

Risk-Adjusted Implementation Strategy

The execution must prioritize funding certainty over interest rate optimization. Roche should over-subscribe the bond offering even at a premium to ensure the deal does not fail due to a sudden market freeze. To mitigate operational friction, Roche must grant gRED autonomy over its research budget, reporting directly to the Group CEO rather than the head of Roche Pharma R&D. This structural protection is the contingency plan against cultural erosion.

Executive Review and BLUF

BLUF

Roche must finalize the Genentech acquisition immediately by raising the offer price to 95.00 USD per share. While the 2009 credit environment is restrictive, the strategic necessity of capturing 100 percent of Genentech cash flows and eliminating structural redundancies is paramount. The incremental 4 billion USD cost of a negotiated settlement is a necessary insurance premium against a failed hostile bid and the subsequent loss of key scientific personnel. Funding is achievable through a multi-currency bond strategy, provided Roche acts before further market volatility occurs. Final verdict: APPROVED FOR LEADERSHIP REVIEW.

Dangerous Assumption

The analysis assumes that the Genentech R&D engine will maintain its historical productivity once the financial incentives of independence are removed. The transition from equity-based biotech compensation to a more traditional corporate structure remains the single most likely point of failure for long-term value creation.

Unaddressed Risks

• Interest Rate Risk: A sudden spike in benchmark yields during the five-week tender period could increase the annual debt service cost by over 400 million USD, potentially threatening the Roche credit rating.
• Regulatory Scrutiny: While antitrust concerns are minimal, the political environment in the United States regarding drug pricing for biologics could shift, compressing the margins that the valuation assumes are permanent.

Unconsidered Alternative

The team did not evaluate a partial buyback of 10 to 15 percent of shares to gain a super-majority without a full merger. This would have required significantly less debt while granting Roche greater control over board decisions and dividend policy, serving as a mid-point between the current state and a full 45 billion USD acquisition.